China NT Pharma Group Company Limited, together with its subsidiaries, researches and develops, manufactures, sells, and distributes pharmaceutical products in the People’s Republic of China and internationally. More Details
Worrying balance sheet with weak fundamentals.
Share Price & News
How has China NT Pharma Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1011 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 1011's weekly volatility (11%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1011 underperformed the Hong Kong Pharmaceuticals industry which returned 20.9% over the past year.
Return vs Market: 1011 underperformed the Hong Kong Market which returned 29.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is China NT Pharma Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StAre Insiders Buying China NT Pharma Group Company Limited (HKG:1011) Stock?
7 months ago | Simply Wall StChina NT Pharma Group (HKG:1011) Has Debt But No Earnings; Should You Worry?
10 months ago | Simply Wall StNeed To Know: China NT Pharma Group Company Limited (HKG:1011) Insiders Have Been Buying Shares
Is China NT Pharma Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1011's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1011's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1011 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.
PE vs Market: 1011 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1011's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1011 is overvalued based on its PB Ratio (12.5x) compared to the HK Pharmaceuticals industry average (1.3x).
How is China NT Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China NT Pharma Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has China NT Pharma Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1011 is currently unprofitable.
Growing Profit Margin: 1011 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1011 is unprofitable, and losses have increased over the past 5 years at a rate of 51.6% per year.
Accelerating Growth: Unable to compare 1011's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1011 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 1011 has a negative Return on Equity (-853.04%), as it is currently unprofitable.
How is China NT Pharma Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1011's short term assets (CN¥577.0M) do not cover its short term liabilities (CN¥1.2B).
Long Term Liabilities: 1011's short term assets (CN¥577.0M) exceed its long term liabilities (CN¥116.2M).
Debt to Equity History and Analysis
Debt Level: 1011's debt to equity ratio (3754.7%) is considered high.
Reducing Debt: 1011's debt to equity ratio has increased from 29.1% to 3754.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 1011 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1011 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is China NT Pharma Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1011's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1011's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1011's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1011's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1011 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1011's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Ng (56 yo)
Mr. Tit Ng, also known as David, has been the Chief Executive Officer, and Chairman of China NT Pharma Group Company Limited since 1995. He is a Co-Founder of NT Pharma Group Company Limited. Mr. Ng was ap...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD969.61K) is above average for companies of similar size in the Hong Kong market ($USD230.00K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: 1011's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: 1011's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China NT Pharma Group Company Limited's company bio, employee growth, exchange listings and data sources
- Name: China NT Pharma Group Company Limited
- Ticker: 1011
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$245.698m
- Shares outstanding: 1.90b
- Website: https://www.ntpharma.com
Number of Employees
- China NT Pharma Group Company Limited
- S2 The Bund Finance Center
- 11th Floor
China NT Pharma Group Company Limited, together with its subsidiaries, researches and develops, manufactures, sells, and distributes pharmaceutical products in the People’s Republic of China and internatio...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:17|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.